Free Access
| Issue |
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
|
|
|---|---|---|
| Page(s) | 1208 - 1211 | |
| Section | M/S Revues | |
| DOI | https://doi.org/10.1051/medsci/2019250 | |
| Published online | 06 January 2020 | |
Med Sci (Paris) 2019 ; 35: 1208–1212
Caractéristiques des anticorps ayant reçu une dénomination commune internationale, cités dans ce numéro de médecine/sciences1
| Anticorps (DCI*) | Cible(s) | Nom commercial | Firmes |
|---|---|---|---|
| abciximab | GPIIbIIIa/ | Réopro | Centocor / Janssen / |
| CD11b/CD18 | Eli Lilly and Company | ||
| αvβ3 | |||
| adalimumab | TNF-α | Humira | Cambridge Antibody Technology(CAT) / AbbVie |
| adécatumumab | EpCAM | - | Micromet / Merck |
| aducanumab | amyloïde β | - | Neurimmune / Biogen |
| (A-β fibrillaire) | |||
| ado-trastuzumab emtansine (DM1) | HER2/neu | Kadcyla | Genentech (Roche) / Lonza |
| aérubumab | Ps°°°° | Aerucin | Aridis Pharmaceuticals |
| alemtuzumab | CD52 | Lemtrada | Sanofi Genzyme |
| alirocumab | PCSK9++ | Praluent | Sanofi-Aventis |
| anifrolumab | IFNAR1 | - | Medimmune LLC / AstraZeneca |
| atézolizumab | PD-L1 | Tecentriq | Genentech (Roche+) |
| avélumab | PD-L1 | Bavencio | Merck Sharp & Dohme / Pfizer |
| basiliximab | IL-2Rα (CD25) | Simulect | Novartis |
| bavituximab | Phosphatidylsérine | - | Peregrine Pharmaceuticals |
| bélantamab mafodotine. | BCMA (TNFRSF17) | - | GlaxoSmithKline |
| bélimumab | BLyS (BAFF) | Benlysta | GlaxoSmithKline |
| benralizumab | IL-5R | Fasenra | AstraZeneca |
| bévacizumab | VEGF-A | Avastin | Roche |
| bézlotoxumab | entérotoxine B | Zinplava | Merck Sharp & Dohme |
| Clostridium difficile | |||
| bimékizumab | IL-17A/F | - | UCB |
| blésélumab | CD40 | - | Kiowa Kirin Pharmaceuticals |
| blinatumomab | CD3εxCD19 | Blincyto | Micromet / Amgen |
| bococizumab | PCSK9 | - | Pfizer |
| brentuximab védotine | CD30 | Adcetris | Seattle Genetics |
| burosumab | FGF23 | Crysvita | Kyowa Hakko Kirin Pharma |
| cabiralizumab | CSF1-R (CD115) | - | Five Prime Therapeutics/ Bristol-Myers Squibb |
| camrélizumab | PD-1 | - | Jiangsu HengRui Medicine |
| canakinumab | IL-1β | Ilaris | Novartis |
| caplacizumab | vWF | Cablivi | Sanofi |
| catumaxomab | CD3ε x EpCAM | Removab | Fresenius Biotech / Trion Pharma |
| cémiplimab | PD-1 (CD279) | Libtayo | Regeneron / Sanofi |
| cergutuzumab amunaleukin | ACE | - | Roche |
| certolizumab pégol | TNF-α | Cimzia | UCB Pharma |
| cétrélimab | PD-1 (CD279) | - | Janssen |
| cétuximab | EGF-R | Erbitux | Imclone / Merck Serono |
| conatumumab | TRAIL-R2(DR5, APO-2) | - | Amgen / Takeda |
| concizumab | TFPI°°° | - | Novo Nordisk |
| cosfroviximab | Gp surface Ebola virus≠ | ZMapp | Mapp Biopharmaceuticals |
| crénézumab | amyloïde β(A-β fibrillaire) | - | Genentech (Roche) |
| cusatuzumab | CD70 | - | Argenx / Janssen Cilag |
| dacétuzumab | CD40 | - | Seattle Genetics / Genentech |
| daclizumab | CD25 (IL-2Rα) | Zinbryta | Protein Design Labs BioPharma / Biogen / AbbVie |
| dapirolizumab pégol | CD40L (CD154) | - | UCB Pharma |
| daratumumab | CD38 | Darzalex | Janssen |
| dénosumab | RANKL | Prolia / Xgeva | Amgen |
| dépatuxizumab madofotine | EGF-RvIII | - | AbbVie |
| dinutuximab bêta | GD2 | Qarziba | EUSA Pharma / Jazz Pharmaceuticals |
| diridavumab | HA## | - | Janssen |
| drozitumab | TRAIL-R2(DR5, APO-2) | - | Genentech (Roche) |
| dupilumab | IL-4/IL-13Rα | Dupixent | Regeneron / Sanofi |
| durvalumab | PD-L1 | Imfinzi | MedImmune LLC / AstraZeneca |
| éculizumab | C5 | Soliris | Alexion Pharmaceuticals |
| éfalizumab | CD11a | Raptiva | Genentech / Merck Serono |
| éfungumab | Hsp90≠≠ | Mycograb | NeuTec Pharma / Novartis |
| élotuzumab | SLAMF7 | Empliciti | Bristol-Myers Squibb |
| émactuzumab | CSF1-R (CD115) | - | Genentech / Roche |
| émicizumab | facteurs IXa x X | Hemlibra | Chugai (Roche) |
| enfortumab védotin | nectine 4 | - | Seattle Genetics |
| énoblituzumab. | B7-H3 (CD276) | - | MacroGenics |
| eptinézumab | CGRP$$ | - | Alder Biopharmaceuticals |
| érénumab | CGRP | Aimovig | Amgen / Novartis |
| erlizumab | CD18 | - | Genentech (Roche) |
| ertumaxomab | HER2/neu x CD3εx RFcγI/II/III | - | Fresenius Biotech |
| étanercept | TNF-α | Enbrel | Pfizer |
| étigilimab | TIGIT | - | Oncomed / Mereo BioPharma |
| énoblituzumab | B7-H3 (CD276) | - | MacroGenics |
| évolocumab | PCSK9++ | Repatha | Amgen |
| farlétuzumab | Folate receptor 1 | - | Morphotek |
| felvizumab | F§§(protéine de fusion) | - | GlaxoSmithKline |
| flotétuzumab | CD123 x CD3e | - | MacroGenics |
| foravirumab | gp I et gpIII§§§ | - | Crucell / Sanofi Pasteur |
| frémanézumab | CGRP | Ajovy | Teva |
| frésolimumab | TGF-β | - | Genzyme (Sanofi) |
| futuximab | EGFR (Erb1, HER1) | - | Symphogen |
| galcanézumab | CGRP | Emgality | Eli Lilly & Company |
| galiximab | CD80 | Biogen (ex-Biogen Idec) | |
| ganténérumab | amyloïde β(A-β fibrillaire) | - | Roche |
| gédivumab | HA | - | Genentech (Roche) |
| gemtuzumab ozogamicin | CD33 | Mylotarg | Celltech / Wyeth |
| golimumab | TNF-α | Simponi | Janssen |
| grémubamab | PcrV et PsI++++ | - | MedImmune (AstraZeneca) |
| guselkumab | IL-23Rp19 | Tremfya | Janssen |
| ibalizumab | CD4 | Trogarzo | Theratechnologies |
| ibritumomab tiuxetan | CD20 | Zevalin | Spectrum Pharmaceuticals / Acrotech Biopharma |
| idarucizumab | Dabigatran | Praxbind | Boehringer Ingelheim |
| inclacumab | Sélectine P | - | Roche |
| infliximab | TNF-α | Remicade | NYU°° / Janssen |
| inotuzumab ozogamicine | CD22 | Besponsa | Pfizer |
| ipilimumab. | CTLA-4 | Yervoy | Medarex / Bristol-Myers Squibb |
| isatuximab | CD38 | - | Sanofi |
| iscalimab | CD40 | - | Xoma / Novartis |
| ixékizumab | IL-17A | Taltz | Eli Lilly & Company |
| lacnotuzumab | CSF-R (CD115) | - | Novartis |
| lanadélumab | kallicréine | Takhzyro | Takeda / Shire |
| larcaviximab | Gp surface Ebola virus | ZMapp | Mapp Biopharmaceuticals |
| lenvervimab | Ag HBs§ | - | GC Pharma |
| léronlimab | CCR5 | - | CytoDyn |
| lexatumumab | TRAIL-R2(DR5, APO-2) | - | Human Genome Sciences / Cambridge Antibody Technology |
| ligélizumab | IgE | - | Novartis |
| lirilumab | KIR2DL1/L2/L3- | - | Innate Pharma / Bristol-Myers Squibb |
| loncastuximab tésirine | CD19 | - | ADC Therapeutics |
| lucatumumab | CD40 | - | Chiron / Xoma / Novartis |
| lulizumab pégol | CD28 | - | Bristol-Myers Squibb |
| lumiliximab | CD23 (RFcεII) | - | Biogen Idec |
| mapatumumab | TRAIL-R1 (DR4) | - | Human Genome Sciences (GlaxoSmith Kline)/ Cambridge Antibody Technology (AstraZeneca) |
| magrolimab | CD47 | - | Forty Seven Inc. |
| mirvétuximab soravtansine | FOLR1 | - | ImmunoGen |
| mitazalimab | CD40 | - | Alligator Biosciences / Janssen |
| modotuximab | HER1 (ErbB-1) | - | Symphogen |
| mogamulizumab | CCR4 | Poteligeo | BioWa / Kyowa Hakko Kirin Pharma |
| monalizumab | CD94/NKG2A | - | Innate Pharma / AstraZeneca |
| mosunétuzumab | CD20 x CD3e | - | Genentech (Roche) |
| motavizumab | F(protéine de fusion) | Numax | MedImmune (AstraZeneca) |
| moxétumomab pasudotox | CD22 | Lumoxiti | AstraZeneca / Innate Pharma |
| muromonab | CD3ε | Orthoclone OKT3 | Janssen-Cilag |
| naptumomab estéfénatox | 5T4°°°°° | - | Active Biotech |
| natalizumab | α4β1(VLA-4$) | Tysabri | Biogen / Élan |
| nécitumumab | EGFR | Portrazza | Eli Lilly & Company |
| niversimab | F(protéine de fusion) | - | MedImmune (AstraZeneca)Sanofi Pasteur |
| nivolumab | PD-1 | Opdivo | Medarex / Bristol-Myers Squibb |
| obiltoxaximab | PA# exotoxine(Anthrax) | Anthim | Elusys Therapeutics |
| obinutuzumab | CD20 | Gazyvaro / Gazyva | Glycart Biotechnology (Roche) |
| ocrélizumab | CD20 | Ocrevus | Roche |
| ofatumumab | CD20 | Arzerra | Genmab / GlaxoSmithKline |
| omalizumab | IgE | Xolair | Novartis |
| oportuzumab monatox | EpCAM | Vicinium | Viventia Bio |
| otélixizumab | CD3 | - | Tolerx / GlaxoSmithKline |
| otilimab | GM-CSF | - | Morphosys / GlaxoSmithKline |
| oxélumab | Ox40L (CD223) | - | Genentech (Roche) |
| pagibaximab | Acide lipotéichoïque$$$ | - | Biosynexus |
| palivizumab | VRS+++ | Synagis | MedImmune (AstraZeneca) |
| panitumumab | EGFR | ||
| patéclizumab | Lymphotoxine-α | - | Genentech (Roche) |
| pembrolizumab | PD-1 | Keytruda | Merck Sharp and Dohme |
| pertuzumab | HER2/neu | Perjeta | Genentech (Roche) |
| pexélizumab | C5 | - | Alexion Pharmaceuticals |
| pidilizumab | PD-1 (CD279) | - | Medivation |
| polatuzumab védotine-piqq | CD79b | Polivy | Genentech (Roche) |
| porgaviximab | Gp de surface | ZMapp | Mapp Biopharmaceutical / Public Health Agency of Canada |
| prézalizumab | ICOS-L (CD275) | - | Amgen |
| ramucirumab | VEGF-R2 (KDR) | Cyramza | Eli Lilly & Company |
| ranibizumab | VEGF-A | Lucentis | Genentech (Roche) / Novartis |
| ravagalimab | CD40 | - | AbbVie |
| ravulizumab | C5 | Ultomiris | Alexion Pharmaceuticals |
| raxibacumab | PA exotoxine(Anthrax) | ABthrax | Human Genome Sciences / GlaxoSmithKline |
| rélatlimab | LAG-3 (CD223) | - | Bristol-Myers Squibb |
| risankizumab | IL-23Rp19 | - | Boehringer Ingelheim / AbbVie |
| rituximab | CD20 | Rituxan/Mabthera | Genentech (Roche) |
| rolédumab | Rhésus D | - | LFB° Group |
| rontalizumab | IFN-α | - | Genentech / Chugai Pharmaceuticals |
| rovalpituzumab tésirine | DLL3### | Rova-T | Stemcentrx / Abbvie |
| rovélizumab | CD18 | - | Icos Corp. (Eli Lilly & Company) |
| ruplizumab | CD40L (CD154) | Antova | Biogen |
| sacituzumab govitécan | Trop-2 | - | Immunomedics |
| sarilumab | IL-6Rα (CD126) | Kevzara | Regeneron / Sanofi Aventis |
| sécukinumab | IL-17A | Cosentyx | Novartis |
| sélicrélumab | CD40 | - | Roche |
| sévirumab | gH### | - | PDL BioPharma / Novartis |
| sibrotuzumab | Fibroblastactivation protein (FAP) | - | Boehringer Ingelheim Pharma |
| sintilimab | PD-1 (CD279) | Tyvit | Innovent Biologics / Eli Lilly and Co |
| spartalizumab | PD-1 (CD279) | - | Novartis |
| suptavumab | F(protéine de fusion) | - | Regeneron Pharmaceuticals |
| suvratoxumab | Staphylococcus aureus alpha toxin | - | MedImmune (AstraZeneca) |
| tavolimab | OX-40 (CD134) | - | MedImmune (AstraZeneca) |
| téfibazumab | ClfA#### | Aurexis | Inhibitex (Bristol-Myers Squibb) |
| ténéliximab | CD40 | - | ? |
| téplizumab | CD3 | - | ProventionBio |
| théralizumab | CD28 | - | TeGenero Immuno Therapeutics / TheraMAB |
| tigatuzumab | TRAIL-R2(DR5, APO-2) | - | Daiichi Sankyo |
| tiragolumab | TIGIT | - | Genentech (Roche) |
| tislélizumab | PD-1 (CD279) | - | Beigene / Celgene (Bristol-Myers Squibb) |
| tocilizumab | IL-6Rα (CD126) | Actemra/RoActemra | Chugai (Roche) |
| toralizumab | CD40L (CD154) | - | Idec Pharmaceuticals |
| toripalimab | PD-1 (CD279) | - | Shanghai Junshi Bioscience Co |
| tositumomab | CD20 | Bexxar | GlaxoSmithKline |
| trastuzumab | HER2/neu | Herceptine | Genentech / Roche |
| trastuzumab déruxtécan | HER2/neu | - | Daiichi Sankyo |
| trastuzumab duocarmazine | HER2/neu | - | Synthon Biopharmaceuticals BV |
| trémélimumab | CTLA-4 (CD152) | - | Pfizer / Medimmune LLCAstraZeneca |
| ublituximab | CD20 | - | LFB° Group / TG Therapeutics |
| urélumab | 4-1BB (CD137) | - | Bristol-Myers Squibb |
| ustékinumab | IL-23Rp40 | Stelara | Janssen |
| utomilumab | 4-1BB (CD137) | - | Pfizer |
| vanalimab | CD40 | - | Alligator BioScience /Janssen Biotech |
| varlilumab | CD27 | - | Celldex therapeutics |
| védolizumab | α4β7 | Entyvio | Takeda |
| veltuzumab | CD20 | - | Immunomedics |
| volociximab | α5β1 | - | PDL BioPharma / Biogen Idec |
| vopratélimab | ICOS (CD278) | - | Jounce Therapeutics |
++++
anticorps bispécifique anti-protéines sécrétrices de type III (PcrV) et anti-exopolysaccharide (PsI) de la paroi de Pseudomonas aeruginosa
####
Épitope de fixation à la fibrine du facteur d’agglutination A (ClfA) de la paroi de Staphylococcus aureus
§§
Cocktail de deux AcM dirigés contre les sites antigéniques des glycoprotéines I (pour CR57) et III (pour CR4098) de l’enveloppe du virus de la rage (RV, rhabdovirus de la rage)
© 2019 médecine/sciences – Inserm
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.